Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30629992 | 1.00 | TDP1 (0.45) | TDP1CASP3LMNATP53KMT2A | |
| SCHEMBL26115282 | 1.00 | TDP1 (0.45) | TDP1CASP3LMNATP53KMT2A | |
| SCHEMBL26116623 | 0.84 | TDP1 (0.45) | TDP1CASP3LMNATP53KMT2A | |
| SCHEMBL26110314 | 0.84 | TDP1 (0.45) | TDP1CASP3LMNATP53KMT2A | |
| SCHEMBL26110317 | 0.84 | TDP1 (0.45) | TDP1CASP3LMNATP53KMT2A | |
| SCHEMBL30629983 | 0.84 | TDP1 (0.45) | TDP1CASP3LMNATP53KMT2A | |
| SCHEMBL26116619 | 0.84 | TDP1 (0.45) | TDP1CASP3LMNATP53KMT2A | |
| SCHEMBL30629984 | 0.84 | TDP1 (0.45) | TDP1CASP3LMNATP53KMT2A | |
| SCHEMBL13669517 | 0.83 | LMNA (0.53) | TDP1LMNATP53ALDH1A1POLB | |
| SCHEMBL31671417 | 0.83 | LMNA (0.53) | TDP1LMNATP53ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092038-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250248973-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. | 2025-08-07 | — | — | US | disclosed |
| WO-2023196556-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CORBUS PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250248973-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CNR1, CNR2, GPR119 | TDP1 3456/4885CASP3 2568/4885LMNA 4038/4885 |
| US-20260092038-A1 | CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF | CNR1, CNR2, GPR119 | TDP1 3451/4885CASP3 2583/4885LMNA 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.